Morgan Stanley believes “favorable” Phase 1a data for Janux Therapeutics’ (JANX) JANX007 in metastatic castration-resistant prostate cancer provides a “positive readthrough” to Vir Biotechnology’s (VIR) masked TCE pipeline, the analyst tells investors. The firm, which reminds investors that initial Phase 1 monotherapy data from VIR-5818 and VIR-5500 are expected in Q1 of 2025, has an Equal Weight rating and $10 price target on Vir shares, which are up $1.95, or 24%, to $10.10 in pre-market trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology holds a virtual investor update
- Vir Biotechnology announces results from SOLSTICE trial
- Vir Biotechnology gets positive opinion on orphan drug designation for Tobevibar
- Vir Biotechnology reports ‘positive’ end-of-treatment data from MARCH study
- JMP Securities healthcare analysts hold an analyst/industry conference call